Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment

NCT03713957 is registered in ClinicalTrials.gov with Alkahest, Inc. as lead sponsor.

NCT NCT03713957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03713957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
Lead sponsor
Alkahest, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 12, 2018
Completion date
July 20, 2020
Enrollment
79 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease